Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Pralatrexate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,047,251Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Mundipharma, Mundipharma Medical , and Acrotech Biopharma Enter into Agreement
    Mundipharma, Mundipharma Medical , and Acrotech Biopharma Enter into Agreement

    01 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/mundipharma-international-corporation-limited-mundipharma-medical-company-and-acrotech-biopharma-inc-enter-agreement-to-transfer-license-of-folotyn-pralatrexate-in-china-to-casi-pharmaceuticals-301889557.html

    PR NEWSWIRE
    01 Aug 2023
    Share Share
    New virtual screening strategy identifies existing drug inhibits COVID-19
    New virtual screening strategy identifies existing drug inhibits COVID-19

    31 Dec 2020

    // SCIENCEDAILY

    https://www.sciencedaily.com/releases/2020/12/201231141456.htm

    SCIENCEDAILY
    31 Dec 2020
    Share Share
    The top 10 most-expensive meds in the U.S.—and they're not the usual suspects
    The top 10 most-expensive meds in the U.S.—and they're not the usual suspects

    13 Jun 2019

    // Eric Sagonowsky FIERCE PHARMA

    https://www.fiercepharma.com/pharma/most-expensive-meds-u-s-topped-by-novartis-and-spark-gene-therapies

    Eric Sagonowsky FIERCE PHARMA
    13 Jun 2019
    Share Share
    Deals and M&As this week: Alnylam Pharmaceuticals, Novartis
    Deals and M&As this week: Alnylam Pharmaceuticals, Novartis

    25 Jan 2019

    // PHARMA TECH

    https://www.pharmaceutical-technology.com/news/deals-and-mas-this-week-alnylam-pharmaceuticals-novartis/

    PHARMA TECH
    25 Jan 2019
    Share Share
    Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M
    Spectrum Pharmaceuticals sells marketed drugs to Aurobindo subsidiary for up to $300M

    18 Jan 2019

    // Alaric Dearment MEDCITY NEWS

    https://medcitynews.com/2019/01/spectrum-pharmaceuticals-sells-marketed-drugs-to-aurobindo-subsidiary-for-up-to-300m/?rf=1

    Alaric Dearment MEDCITY NEWS
    18 Jan 2019
    Share Share
    Teva Pharma's Pralatrexate tentatively approved in US an anti-cancer therapy
    Teva Pharma's Pralatrexate tentatively approved in US an anti-cancer therapy

    18 Jan 2016

    // FDA

    https://www.pharmacompass.com/pdf/news/teva-pharmas-pralatrexate-tentatively-approved-in-us-an-anti-cancer-therapy-1453550605.pdf

    FDA
    18 Jan 2016
    Share Share